Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis

被引:6
|
作者
Niu, Xiao-Wei [1 ]
Zhang, Jing-Jing [2 ]
Bai, Ming [3 ]
Peng, Yu [3 ]
Zhang, Zheng [3 ]
机构
[1] Lanzhou Univ, Clin Med Sch 1, Lanzhou, Gansu, Peoples R China
[2] Baiyin Second Peoples Hosp, Baiyin, Peoples R China
[3] Lanzhou Univ, Dept Cardiol, Hosp 1, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
关键词
Glycoprotein IIb/IIIa inhibitors; Meta-analysis; Myocardial reperfusion; Thrombectomy; Percutaneous coronary intervention; MANUAL THROMBUS ASPIRATION; PRIMARY ANGIOPLASTY; COMBINATION TREATMENT; INFARCTION; ABCIXIMAB; TIROFIBAN; PERFUSION; IMPACT; EPTIFIBATIDE; MORTALITY;
D O I
10.11909/j.issn.1671-5411.2017.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Suboptimal myocardial reperfusion is common in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Furthermore, it results in increased infarct size and mortality rates. We performed a meta-analysis to evaluate the role of aspiration thrombectomy (AT) combined with intracoronary administration of glycoprotein IIb/IIIa inhibitors (GPI) in the improvement of myocardial reperfusion and clinical outcomes. Methods PubMed, Embase, Web of Science, and CENTRAL databases were searched for randomized controlled trials (RCTs) investigating combined AT and intracoronary GPI treatment versus AT alone. Outcomes of interest were thrombolysis in myocardial infarction myocardial perfusion grade (TMPG), infarct size (IS) assessed by cardiac magnetic resonance imaging, left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE) at short-term (<= 1 month) and long-term (6. 12 months) follow-up, and bleeding complications during the hospital stay. Results Eight trials involving 923 patients were included. Compared with AT alone, combined AT and intracoronary GPI significantly increased TMPG 3 flow (RR: 1.15, 95% CI: 1.04 to 1.26), reduced IS [mean difference (MD): -3.46, 95% CI: -5.18 to -1.73], and improved LVEF (MD: 1.44, 95% CI: 0.54 to 2.33). Furthermore, GPI use decreased the risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98). There was no significant difference between the two groups in the incidence of minor and major bleeding complications. Conclusions Our findings showed that compared with AT alone, combined AT and intracoronary GPI treatment resulted in improved myocardial reperfusion, better cardiac function, and MACE-free survival benefits at the long-term follow-up for patients with STEMI undergoing PPCI.
引用
收藏
页码:614 / 623
页数:10
相关论文
共 50 条
  • [21] A Comparison of Intracoronary with Intravenous Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials
    Fu, Gang
    Jia, Lei
    Zhao, Xin
    Wang, Yibo
    Chen, Xiaohui
    Yang, Yang
    Lu, Na
    Zhao, Wei
    Hui, Rutai
    Zheng, Yang
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2012, 25 (03) : 223 - 234
  • [22] Meta-Analysis of Randomized Controlled Trials Comparing Intracoronary and Intravenous Administration of Glycoprotein IIb/IIIa Inhibitors in Patients With ST-Elevation Myocardial Infarction
    Wang, Yongsin
    Wu, Boting
    Shu, Xianhong
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (08) : 1124 - 1130
  • [23] Safety and efficacy of early administration of tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis
    Liu Yangchun
    Su Qiang
    Li Lang
    CHINESE MEDICAL JOURNAL, 2014, 127 (06) : 1126 - 1132
  • [24] Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
    Ibebuogu, Uzoma N.
    Bolorunduro, Oluwaseyi
    Giri, Smith
    Dagogo-Jack, Sam
    Smith, Blake G.
    Kar, Saibal
    Reed, Guy L.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2015, 15 (04) : 275 - 285
  • [25] Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
    Uzoma N. Ibebuogu
    Oluwaseyi Bolorunduro
    Smith Giri
    Sam Dagogo-Jack
    Blake G. Smith
    Saibal Kar
    Guy L. Reed
    American Journal of Cardiovascular Drugs, 2015, 15 : 275 - 285
  • [26] Upstream vs Deferred Administration of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction - Insights From Randomized Clinical Trials
    Dong, Lili
    Zhang, Feng
    Shu, Xianhong
    CIRCULATION JOURNAL, 2010, 74 (08) : 1617 - 1624
  • [27] Efficacy and Safety of Glycoprotein IIb/IIIa Receptor Antagonists for Patients Undergoing Percutaneous Coronary Intervention Within Twelve Hours of Fibrinolysis
    Belle, Loic
    Fourny, Magali
    Reynaud, Thomas
    Hammer, Laure
    Vanzetto, Gerald
    Labarere, Jose
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2011, 78 (03) : 376 - 384
  • [28] Trends of Use and Outcomes Associated With Glycoprotein-IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
    Gellatly, Rochelle M.
    Connell, Cia
    Tan, Christianne
    Andrianopoulos, Nick
    Ajani, Andrew E.
    Clark, David J.
    Nanayakkara, Shane
    Sebastian, Martin
    Brennan, Angela
    Freeman, Melanie
    O'Brien, Jessica
    Selkrig, Laura A.
    Reid, Christopher M.
    Duffy, Stephen J.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (05) : 414 - 422
  • [29] Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial
    Huber, Kurt
    Holmes, David R., Jr.
    van 't Hof, Arnoud W.
    Montalescot, Gilles
    Aylward, Philip E.
    Amadeo Betriu, G.
    Widimsky, Petr
    Westerhout, Cynthia M.
    Granger, Christopher B.
    Armstrong, Paul W.
    EUROPEAN HEART JOURNAL, 2010, 31 (14) : 1708 - 1716
  • [30] Intracoronary antithrombotic therapy during primary percutaneous coronary intervention in patients with STEMI: A systematic review and network meta-analysis
    Geum, Min Jung
    Yu, Yun Mi
    Jeon, Jinyoung
    Lee, Hyun Woo
    Shin, Jaekyu
    Chung, Woo-Young
    Hahn, Jongsung
    Ah, Young-Mi
    THROMBOSIS RESEARCH, 2024, 233 : 127 - 134